EUCTR2022-003398-51-DE招募中1 期
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP - R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest0 个研究点目标入组 80 人开始时间: 2023年1月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •(1)Patient has provided written informed consent and is able and willing to comply with the study protocol and protocol mandated hospitalizations according to ICH and local regulations.
- •(2)Patient (male, female, non-binary) is
- •a)Age > 80 years, medically fit to receive the combination therapy OR
- •b)Age 61-80 years, medical non-fit and not eligible for R-CHOP-like therapies.
- •(3)Patient has histologically confirmed aggressive lymphoma.
- •Note: transformed follicular lymphoma and composite lymphoma can be included as long as the low-grade component had not obtained treatment.
- •(4)Baseline biopsy material is available for central review.
- •(5)Female patients considered as women of childbearing potential (WOCBP, see section 5.2.7 for definition) and male patients with female partners considered as WOCPB must
- •a)agree to either remain completely abstinent (refrain from heterosexual intercourse) or to use at least one effective contraceptive methods that results in a failure rate of < 1% per year from screening until:
- •oAt least 4 months after last dose of glofitamab, 9 months after last dose of polatuzumab vedotin, 12 months after last dose of rituximab or 18 months after last dose of obinutuzumab, whichever is longer, if the patient is female
- •oAt least 4 months after last dose of rituximab, obinutuzumab and glofitamab or 6 months after last dose of polatuzumab vedotin, whichever is longer, if the patient is male
- •b)refrain from donating ova (female patients) or donating sperm (male patients) during the same period as stated in a).
- •c)in case of male patients with pregnant female partners, remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom to avoid exposing the embryo.
- •Female patients who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile, see section 5.2.7) as well as azoospermic male patients do not require contraception.
- •(6)Patient did not receive any prior lymphoma therapy.
- •Note: Except for a corticosteroid prephase.
- •(7)Patient has a ECOG performance status of = 2.
- •Note: Subjects with an initial ECOG performance status of 3 may be considered during screening if the performance status is DLBCL-related and if pre-phase treatment (not more than 100 mg steroids/day up to 7 days prior to Cycle 1 Day 1) during the screening phase results in an improvement of ECOG performance status to = 2 prior to enrollment.
- •(8)Patient has a life expectancy (in the opinion of the investigator) of at least 12 weeks.
- •(9)Patient has adequate liver function:
- •a)Total bilirubin =1.5 x ULN (=3 x ULN in patients with Gilbert’s syndrome).
- •b)AST (aspartate aminotransferase)/ALT (alanine aminotransferase), ALP (alkaline phosphatase) =3 x ULN.
- •oPatients with bone marrow or liver involvement: ALP =5 x ULN.
- •oPatients with documented liver involvement: AST and/or ALT =5 x ULN.
- •c)Albumin = 2.5 g/dL.
- •(10)Patient has adequate hematological function:
- •a)Neutrophil count of =1.5 x 109 cells/L (1,500/µL).
- •b)Platelet count of =75 x 109 cells/L (75,000/µL).
- •c)Hemoglobin (Hb) =9.0 g/dL.
- •Note: In case screening procedures are leading to situations that would exclude the patient from study participation (such as Hb value below entry criteria), the patient may still be enrolled into the trial after consultation with the Sponsor.
- •d)For patients not receiving therapeutic anti-coagulation: INR or aPTT = 1.5 x ULN).
- •(11)Patient has adequate renal function:
- •a)Creatinine = 1.5 x
排除标准
- •(1)Patient with CLL, ALL; including CD20+ ALL, lymphoblastic lymphoma, Richter`s transformation, Burkitt lymphoma.
- •(2)Patient = 60 years
- •(3)Patient with known active infection, or reactivation of a latent infection, whether bacterial (e.g., tuberculosis), viral (including, but not limited to severe pneumonia, COVID-19, EBV, CMV, hepatitis B, hepatitis C, and HIV], fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks prior to study enrollment.
- •(4)Patient with current > Grade 1 peripheral neuropathy.
- •(5)Patient with history of confirmed PML.
- •(6)Patient with history of leptomeningeal disease.
- •(7)Patient with current or history of CNS lymphoma.
- •(8)Patient with current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Exceptions are allowed fot this trial.
- •(9)Patient with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the Investigator to be of low likelihood for recurrence), with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate 90%), such as adequately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- •(10)Patient with significant or extensive history of cardiovascular disease (such as NYHA Class = II cardiac disease, [...]) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
- •(11)Patient with active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis (see addendum for a more comprehensive list of autoimmune diseases and immune deficiencies), with exceptions.
- •(12)Patient with uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
- •(13)Patient with history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic.
- •(14)Patient received treatment with any other standard anti-cancer radiotherapy/chemotherapy including investigational therapy (defined as treatment for which there is currently no regulatory authority approved indication) within 4 weeks or five times the elimination half-life of the product, whichever is longer, prior to study enrollment.
- •(15)Patient with prior solid organ transplantation.
- •(16)Patient with prior allogeneic stem cell transplantation.
- •(17)Patient with prior treatment with targeted therapies (e.g., tyrosine kinase inhibitors,[...]) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to study enrollment.
- •(18)Patient with toxicities from prior anti-cancer therapy including immunotherapy that did not resolve to = Grade 1 except for alopecia, endocrinopathy managed with replacement therapy and stable vitiligo.
- •(19)Patient with any history of immune related = Grade 3 AE except for endocrinopathy managed with rep
研究者
相似试验
招募中
1 期
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOPaggressive large B-cell lymphomaMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2022-003398-51-ATInstitut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest125
进行中（未招募）
1 期
Chemotherapy-free combination of PCI-32765 (Ibrutinib) with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and High Tumor BurdeStage II - IV follicular lymphoma grade 1 - 3a and a high tumor burden not previously treatedMedDRA version: 20.0Level: PTClassification code 10016908Term: Follicle centre lymphoma, follicular grade I, II, III stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016910Term: Follicle centre lymphoma, follicular grade I, II, III stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016909Term: Follicle centre lymphoma, follicular grade I, II, III stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005164-15-DEKlinikum der Universität München, Medizinische Klinik und Poliklinik III
进行中（未招募）
1 期
Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor BurdeFollicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated)MedDRA version: 21.1Level: PTClassification code 10016908Term: Follicle centre lymphoma, follicular grade I, II, III stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016909Term: Follicle centre lymphoma, follicular grade I, II, III stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016910Term: Follicle centre lymphoma, follicular grade I, II, III stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004038-13-DEKlinikum der Universität München102
进行中（未招募）
1 期
A clinical study of chemotherapy plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)EUCTR2017-003540-21-ITovartis Pharma AG502
进行中（未招募）
1 期
A clinical study of chemotherapy plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)newly diagnosed FLT3 non-mutated acute myeloid leukemiaMedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864EUCTR2017-003540-21-HUovartis Pharma AG502